Global private equity and venture capital news and research

Seventure, Lundbeckfond lead €5m investment in Enterome

22 Mar 2012

Seventure and Lundbeckfond Ventures have co-led a €5m investment into chronic disease medicine company Enterome.

The investment in the French business follows a €1.5m seed round from Natixis and INRA Transfert.

Enterome said it would use the Series A financing to initiate industrial partnerships in the pharmaceutical and nutrition fields and strengthen its development capabilities.

A new management team at the company has been formed from former founders and executives of Fovea Pharmaceuticals, which was acquired by Sanofi in 2009, and several biomarker specialists.

Bernard Gilly has also been appointed as the new chairman of the board.

Enterome CEO Pierre Belichard said, “The series A round investors – Seventure and Lundbeckfond Ventures – were specifically attracted to Enterome due to the unique nature of its technology, the close relationship to INRA and the opportunity to create unique biomarker diagnostic products meeting unmet medical and market needs.

Both Seventure and Lundbeckfond also took part in the €21.2m Series C financing of UK biotechnology company Syntaxin in November 2010.

Copyright © 2012 AltAssets


Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014